WELIREG becomes the only approved and available treatment in the U.S. for eligible patients with advanced PPGL. RAHWAY, N.J., May 14, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside ...

Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.

Merck (NYSE:MRK) is seeking to have the drug approved for the treatment of patients 12 years and older with advanced, ...

It is the first US approval of “an oral therapy for PPGL,” the FDA said in a press release. The hypoxia-inducible factor 2 alpha inhibitor was previously approved for von Hippel-Lindau disease ...

WELIREG becomes the only approved and available treatment in the U.S. for eligible patients with advanced PPGL. RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the ...